The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …

Systemic therapeutic efficacy is central to determining the outcome of patients with
metastatic colorectal cancer (CRC). In these patients, there is a critical need for predictive …

PURPOSE The development and use of predictive biomarkers to guide treatment decisions
are paramount not only for improving survival in patients with metastatic colorectal cancer …

Highlights•mCRC patients' survival outcomes pose major treatment challenge for
oncologists.•Personalized medicine is an evolving approach for cancer management …

Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

Background: The incorporation of novel biomarkers into therapy selection for patients with
metastatic colorectal cancer (m crc) has significantly improved outcomes. Optimal treatment …

Colorectal cancer (CRC) is a heterogeneous disease representing a therapeutic challenge,
which is further complicated by the common occurrence of several molecular alterations that …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Colorectal cancer remains one of the most common cancers worldwide and is almost
uniformly fatal for those with metastatic disease. Despite this, there is an increasing number …

Simple Summary Despite recent progress in the treatment of metastatic colorectal cancer
patients, novel therapeutic approaches are highly warranted to further improve outcome …